Roche Holding AG plans to buy Spark Therapeutics Inc for US$4.8 billion, a deal that would give the Swiss drugmaker one of the first-ever therapies to treat, and potentially cure, a disease by providing a fix for a patient’s defective genes.
Roche is to pay US$114.50 a share for Philadelphia-based Spark, a 122 percent premium to the biotechnology company’s close in New York trading on Friday.
While the price is rich, Spark shares were trading above US$90 as recently as last year.
The offer was a 19 percent premium to Spark’s 52-week intraday high, Roche said.
Along with French biopharmaceutical company Ipsen SA’s agreement yesterday to acquire Clementia Pharmaceuticals Inc for as much as US$1.3 billion, the Roche deal shows how drug companies are placing big bets on the fraught but lucrative field of rare diseases.
Gene therapies, in particular, are a promising new area of medicine with the potential to cure a wide range of often-rare diseases by replacing or repairing errors in the body’s instruction manual.
Their amazing potential has been matched by breakthrough prices, as companies have sought to charge hundreds of thousands of dollars for them — or more.
The Roche deal’s premium is an outlier, but recent pharmaceutical deals have come with rich valuations.
Acquirers paid an average 45 percent premium in takeovers of listed pharmaceutical and biotechnology companies announced over the past five years, data compiled by Bloomberg show.
Spark’s therapy Luxturna treats a gene-driven form of blindness by injecting a working version of a gene called RPE65. In people with that condition, the working genes can help restore sight.
After Luxturna was approved by US regulators in 2017, Spark said it would charge US$425,000 per eye for the treatment.
Spark was founded in 2013 at Children’s Hospital of Philadelphia. Along with Luxturna, it is developing gene therapies for the bleeding disorder hemophilia, an area where Roche is seeking to broaden its presence.
Spark already has a licensing agreement with Roche’s crosstown rival, Basel-based Novartis AG. Under an agreement struck last year, Novartis has the rights to sell Luxturna outside the US.
MediaTek Inc (聯發科) yesterday announced it would give incentive bonuses totaling NT$1.7 billion (US$59.7 million) to its employees and those at the firm’s major subsidiaries, after the smartphone chip supplier’s revenue hit US$10 billion last year. This is the biggest incentive bonus the Hsinchu-based handset chip designer has ever distributed in its 23-year history. About 17,000 full-time employees of MediaTek and five of its subsidiaries, including Richtek Technology Corp (立錡科技) and Airoha Technology Corp (絡達科技), would receive a “red envelope” of NT$100,000 each, the company said. “Surpassing US$10 billion is just the beginning. We will continue to [grow] on this basis,” MediaTek
TO SPUR REVENUE: The contract chipmaker expects its profit to grow 15 percent this year, outpacing the foundry industry’s projected advance of about 10 percent Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday raised its projected capital spending for this year by 62 percent, a new high, in an attempt to satisfy customer demand for advanced technologies in the production of central processing units, high-performance-computing (HPC) devices and 5G applications. After investing US$17.24 billion last year, TSMC this year plans to spend US$25 billion to US$28 billion on manufacturing equipment and new facilities, including a fab in the US. About 80 percent of the budget would be allocated for developing advanced technologies including 3, 5 and 7-nanometer technologies, the company said. The larger-than-expected capital spending prompted speculation
CHINESE TIE-UP: The firm said its services with Zhejiang Geely would be related to vehicles, parts, intelligent drive systems and automotive ecosystem platforms Apple Inc’s local manufacturing partner Hon Hai Precision Industry Co (鴻海精密), known as Foxconn Technology Group (富士康科技集團) outside of Taiwan, is setting up a vehicle venture, strengthening its automotive capabilities at a time when technology companies, including its California ally, are looking to expand in automaking. Hon Hai is joining forces with Chinese automaker Zhejiang Geely Holding Group Co (浙江吉利控股集團) to provide production and consulting services to global automotive enterprises, the companies said in a statement yesterday. The production and consulting services are related to whole vehicles, parts, intelligent drive systems and automotive ecosystem platforms, Hon Hai said in a filing with
EQUITIES Caution drives TAIEX lower The TAIEX closed lower yesterday as investors locked in their earlier gains because of caution over the outlook for US markets after authorities warned of security threats at US president-elect Joe Biden’s inauguration on Wednesday next week. However, shares of Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) continued to rise due to optimism that the contract chipmaker would deliver positive leads in an investor conference tomorrow, helping the broader market limit losses, dealers said. In addition, reports that a mass evacuation of patients from a northern Taiwan hospital late on Monday — implying possible COVID-19 infections within the
RSS